Pan-coronavirus fusion inhibitors as the hope for today and tomorrow
Accepted date: 09 Oct 2020
Published date: 15 Feb 2021
Copyright
Xinling Wang , Shuai Xia , Yun Zhu , Lu Lu , Shibo Jiang . Pan-coronavirus fusion inhibitors as the hope for today and tomorrow[J]. Protein & Cell, 2021 , 12(2) : 84 -88 . DOI: 10.1007/s13238-020-00806-7
1 |
Bi W, Xu W, Cheng L, Xue J, Wang Q, Yu F, Xia S, Wang Q, Li G, Qin C
|
2 |
Cui J, Li F, Shi ZL (2019) Origin and evolution of pathogenic coronaviruses. Nature Reviews Microbiology 17:181–192
|
3 |
Fosgerau K, Hoffmann T (2015) Peptide therapeutics: current status and future directions. Drug Discov Today 20:122–128
|
4 |
Graham RL, Donaldson EF, Baric RS (2013) A decade after SARS: strategies for controlling emerging coronaviruses. Nature Reviews Microbiology 11:836–848
|
5 |
Hamburger AE, Kim S, Welch BD,Kay MS (2005) Steric accessibility of the HIV-1 gp41 N-trimer region. J Biol Chem 280:12567–12572
|
6 |
Hollmann A, Matos PM, Augusto MT, Castanho MARB, Santos NC (2013) Conjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its action. Plos ONE 8:e60302
|
7 |
Holmes KV (2003) SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 111:1605–1609
|
8 |
Jiang S, Du L, Shi Z (2020) An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerg Microbes Infect 9:275–277
|
9 |
Jiang S, Lin K, Strick N, dlx AR (1993) Hiv-1 inhibition by a peptide. Nature 365:113
|
10 |
Kleine-Weber H, Elzayat MT, Wang LS, Graham BS, Muller MA, Drosten C, Pohlmann S, Hoffmann M (2019) Mutations in the Spike Protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization. J Virol 93:e01381
|
11 |
Konca C, Korukluoglu G, Tekin M, Almis H, Bucak IH, Uygun H, Altas AB, Bayrakdar F (2017) The First Infant Death Associated with Human Coronavirus Nl63 Infection. Pediatr Infect Dis J 36:231–233
|
12 |
Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P
|
13 |
Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, Wang Q, Chan JF, Du L, Yu F
|
14 |
Morfopoulou S, Brown JR, Davies EG, Anderson G, Virasami A, Qasim W, Chong WK, Hubank M, Plagnol V, Desforges M
|
15 |
Nielsen DS, Shepherd NE, Xu WJ, Lucke AJ, Stoermer MJ, Fairlie DP (2017) Orally absorbed cyclic peptides. Chem Rev 117:8094–8128
|
16 |
Ou J, Zhou Z, Dai R, Zhang J,Lan W, Zhao S, Wu J, Donald Seto, Cui L, Zhang G
|
17 |
Veiga A, Martins LG, Riediger I, Mazetto A, Debur MDC, Gregianini TS (2020) More than just a common cold: Endemic coronaviruses OC43, HKU1, NL63, and 229E associated with severe acute respiratory infection and fatality cases among healthy adults. J Med Virol.https://doi.org/10.1002/jmv.26362
|
18 |
Wang C, Hua C, Xia S, Li W, Lu L, Jiang S (2019) Combining a fusion inhibitory peptide targeting the MERS-CoV S2 protein HR1 domain and a neutralizing antibody specific for the S1 protein receptor-binding domain (RBD) showed potent synergism against pseudotyped MERS-CoV with or without mutations in RBD. Viruses-Basel 11:31
|
19 |
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271
|
20 |
Wong AHM, Tomlinson ACA, Zhou DX, Satkunarajah M, Chen K, Sharon C, Desforges M, Talbot PJ, Rini JM (2017) Receptorbinding loops in alphacoronavirus adaptation and evolution. Nat Commun 8:1735
|
21 |
Wu Y, Li C, Xia S, Tian X, Kong Y, Wang Z, Gu C, Zhang R, Tu C, Xie Y
|
22 |
Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S
|
23 |
Xia S, Liu M, Wang C, Xu W,Lan Q, Feng S, Qi F, Bao L, Du L, Liu S
|
24 |
Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA
|
/
〈 | 〉 |